Monitoring the effect of dabigatran (Pradaxa®) is challenging. The aim of this study was to
evaluate if thrombelastography reaction time (TEG® R) could detect the anticoagulant effect …

Dabigatran, a new direct thrombin inhibitor, achieves strong anticoagulation that is more
predictable than warfarin. Nevertheless, a patient on dabigatran therapy (DT) may suffer …

Dabigatran is a direct thrombin inhibitor that has been approved for preventing stroke in
patients with atrial fibrillation. In this study, we aimed to assess the associations between the …

Background Although activated partial prothrombin time (aPTT) has often been used as a
biomarker for evaluating the safety of dabigatran use in patients with non-valvular atrial …

Routine laboratory monitoring is currently not recommended in patients receiving dabigatran
despite its considerable variation in plasma concentration. However, in certain clinical …

Background: The distribution of activated partial thromboplastin time (APTT) in nonvalvular
atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified. Methods …

Purpose: To assess the predicted rate and the factors associated with bleeding events
among patients with non-valvular atrial fibrillation (NVAF) receiving dabigatran therapy …

Dabigatran etexilate is a prodrug that is converted into its active metabolite, dabigatran, by
hydrolysis. Dabigatran is a selective thrombin inhibitor that has been approved for the …

Background/purpose Dabigatran is effective in preventing ischemic stroke and systemic
embolism in patients with atrial fibrillation. Although the therapeutic window for dabigatran is …

Background Knowledge of anticoagulation status during dabigatran therapy may be
desirable in certain clinical situations. Objective To determine the coagulation tests that are …